DisclosureWe earn commission on partner links; ranking is set by clinician-vetted methodology — not advertisers.
Mixed evidence. Some users report mood improvement with weight loss; others report new-onset depression or worsening symptoms. FDA evaluating signal in 2025-2026.
STEP-1 substudy: net positive mood effect at 68 weeks. Real-world: case reports of new-onset depression. FDA reviewed signal in 2024 and found no causal link, but continues monitoring.
Psychiatry community, FDA. No active off-label use for depression treatment specifically.
If you have depression, GLP-1 use should be coordinated with psychiatry. Monitor mood during titration. Suicidal ideation requires immediate medical contact.
Not an off-label indication — a comorbidity flag. If you have depression and obesity, GLP-1s are still on the table but warrant closer monitoring.
Editorial summary. Off-label use is legal but not FDA-evaluated. Insurance typically does not cover off-label prescriptions. Not medical advice.